Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Rhea-AI Summary
Atossa Therapeutics (Nasdaq: ATOS) announced that the U.S. FDA granted Rare Pediatric Disease (RPD) designation to (Z)-endoxifen for treatment of McCune-Albright Syndrome (MAS) in females on May 4, 2026. RPD status may make the program eligible for a Priority Review Voucher (PRV) upon approval; disclosed PRV sales in the last 18–24 months ranged from approximately $100–$205 million. The company cited scientific rationale for (Z)-endoxifen as a potent SERM/D and noted engagement with the FD/MAS clinical and patient community while it defines a clinical development path for MAS.
Positive
- FDA RPD designation for (Z)-endoxifen in McCune-Albright Syndrome
- Potential Priority Review Voucher (PRV) eligibility upon approval valued at $100–$205M (recent disclosed sales)
- Program expansion into a rare pediatric endocrine indication (MAS) in females
- Engagement with FD/MAS Alliance and clinical community to shape development
Negative
- PRV value requires successful regulatory approval; designation alone does not guarantee approval
- Clinical development path for MAS is still being defined, indicating remaining development risk
News Market Reaction – ATOS
In the May 4 session, ATOS gained 9.94%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.3% during that session. Argus tracked a trough of -10.7% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.3x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Earnings and update | Negative | -13.1% | Higher 2025 operating expenses and net loss highlighted in year-end financials. |
| Mar 19 | Leadership additions | Positive | +0.4% | Added senior clinical leaders to advance oncology and rare-disease programs. |
| Mar 12 | Clinical data update | Positive | +5.7% | Presented preclinical (Z)-endoxifen data supporting development in Duchenne muscular dystrophy. |
| Feb 11 | Shareholder letter | Negative | -16.0% | Outlined 2025 progress alongside reverse split and ongoing capital needs. |
| Feb 05 | PRV program update | Positive | +0.8% | Reauthorization of PRV program supporting (Z)-endoxifen opportunity in DMD. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, whether clinical, strategic, or financial, has tended to produce price moves aligned with the apparent positive or negative tone of each event.
Over the past few months, Atossa has advanced (Z)-endoxifen across oncology and rare diseases, securing Rare Pediatric and Orphan Drug designations in DMD, expanding preclinical data, and strengthening clinical leadership. Financial updates showed higher R&D spending, larger net losses, and going-concern language, paired with reverse splits and an at-the-market facility to support funding. Today’s Rare Pediatric Disease designation in McCune-Albright Syndrome extends the regulatory footprint of (Z)-endoxifen into another rare endocrine indication, consistent with the company’s strategy of broad rare-disease development.
Key Terms
rare pediatric disease regulatory
priority review voucher regulatory
mccune-albright syndrome medical
serm/d medical
endocrine disorder medical
fibrous dysplasia medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a Priority Review Voucher ("PRV"), which can be used to obtain priority review for a future application or may be sold or transferred to another sponsor. In the last 18–24 months, disclosed PRV sales have ranged from approximately
"This designation is an important regulatory milestone for Atossa and provides further validation of the potential of (Z)-endoxifen beyond oncology," said Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer. "McCune-Albright Syndrome is a rare and serious pediatric disorder with significant unmet medical need, particularly in young girls affected by hormone dysregulation and early puberty. We believe (Z)-endoxifen has the potential to address key disease drivers and improve outcomes for these patients, while also creating potential non-dilutive value through the Rare Pediatric Disease program.
Dr. Quay continued, "We are pleased to have participated in the Fibrous Dysplasia, McCune-Albright Syndrome Alliance ("FD/MAS Alliance") (https://fdmasalliance.org/) Research Priorities Workshop at Children's Hospital of
Our engagement in this forum underscores our commitment to collaborating with the clinical and patient community as we advance development of (Z)-endoxifen for MAS."
"RPD designation provides a valuable regulatory pathway and opportunities for enhanced engagement with the FDA as we evaluate development strategies for MAS," said Janet Rea, Senior Vice President of Research and Development at Atossa. "We are encouraged by the scientific rationale supporting (Z)-endoxifen in this setting, particularly given its mechanism as a potent SERM/D and its potential to modulate estrogen-driven disease manifestations. We look forward to advancing this program as we further define the clinical development path."
About Rare Pediatric Disease Designation
The FDA's RPD designation is reserved for serious or life-threatening diseases that primarily affect individuals from birth to 18 years old and that meet the definition of a rare disease or condition under Section 526 of the Federal Food, Drug & Cosmetic Act ("FD&C Act"). MAS qualifies as a rare pediatric disease due to its serious manifestations, including gonadotropin-independent precocious puberty, accelerated bone maturation, and endocrine abnormalities affecting children and adolescents.
Drugs granted RPD designation may be eligible for a PRV upon FDA approval of a qualifying New Drug Application or Biologics License Application, provided all statutory criteria are met. A PRV may be used by the sponsor or sold or transferred to another company.
About McCune-Albright Syndrome
MAS is an extremely rare genetic disorder caused by activating mutations in the GNAS gene, leading to mosaic endocrine dysregulation. Because it is so rare and has a broad spectrum of symptoms, diagnosis can be challenging. The disease is characterized by a triad of symptoms: Polyostotic Fibrous Dysplasia: replacement of normal bone with weak, fibrous tissue, leading to fractures, deformities, and pain; Café-au-lait Spots: hyperpigmented skin patches with irregular, "jagged" borders (often described as the "Coast of
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings.
(Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader ("SERM/D") with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company's proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa's (Z)-endoxifen is not approved for any indication.
Atossa has previously received Orphan Drug Designation, as well as RPD for (Z)-endoxifen for the treatment of Duchenne Muscular Dystrophy from the FDA. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a PRV, which can be used to obtain priority review for a future application or may be sold or transferred to another sponsor. In the last 18-24 months, disclosed PRV sales have ranged from
Atossa's (Z)-endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued
More information is available at https://atossatherapeutics.com.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company's development and regulatory strategy and related milestones, including the potential indications that the Company may pursue for (Z)-endoxifen, the potential for (Z)-endoxifen to receive regulatory approval and the timing thereof, the Company's potential eligibility for and the value of a Rare Pediatric Disease Priority Review Voucher, and the potential market and growth opportunities for the Company. Words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: our ability to successfully execute our strategy to shorten our clinical development timelines and pursue a MAS indication or other indications for our lead program, (Z)-endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to receive orphan-drug exclusivity for (Z)-endoxifen for MAS; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
The market value of a PRV is variable and subject to a number of factors beyond our control and reported past PRV sale amounts are not necessarily indicative of PRV sale amounts in the future.
Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-mccune-albright-syndrome-302760919.html
SOURCE Atossa Therapeutics Inc